



Correction to: External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme

Riziero Esposito Abate¹ · Melanie H. Cheetham² · Jennifer A. Fairley³ · Raffaella Pasquale¹ · Alessandra Sacco¹ · Wolstenholme Nicola² · Zandra C. Deans³ · Simon J. Patton² · Nicola Normanno¹

Published online: 9 December 2022
© The Author(s) 2022

Correction to: Virchows Archiv

<https://doi.org/10.1007/s00428-022-03444-y>

In the original published version of the above article contained incorrect Table legend. The Table 2 with correct legend is as follows:

The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Table 2 Next Generation Sequencing panels used for TMB test by participating laboratories

| Panel | N° of laboratories |
|-----------------------------------|--------------------|
| Oncomine Tumor Mutation Load | 6 |
| Custom panel | 5 |
| TruSight Oncology 500 | 4 |
| Oncomine Comprehensive Assay Plus | 3 |
| SureSelect XT-HS | 1 |
| Twist Human Exome plus RefSeq | 1 |
| IDT xGen Pan-Cancer Panel v2.4 | 1 |
| Oncomine Comprehensive Cancer | 1 |
| Nimblegen SeqCap EZ MedExome | 1 |

The original article can be found online at <https://doi.org/10.1007/s00428-022-03444-y>.

✉ Nicola Normanno
nicnorm@yahoo.com

¹ Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, Naples, Italy

² European Molecular Genetics Quality Network (EMQN), Unit 4, Enterprise House, Pencroft Way, Manchester Science Park, Manchester M15 6SE, UK

³ GenQA, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh EH16 4SA, UK

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.